PMID- 12358905
OWN - NLM
STAT- MEDLINE
DCOM- 20021213
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 119
IP  - 1
DP  - 2002 Oct
TI  - CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells 
      and their downregulation is associated with tumour progression.
PG  - 70-8
AB  - Malignant plasma cells (PC) from multiple myeloma (MM) patients 
      characteristically home to the bone marrow (BM). High numbers of tumour cells are 
      found in the peripheral blood (PB) only at end-stage disease (secondary plasma 
      cell leukaemia, PCL) in a minority of patients. Using flow cytometric and 
      fluorescence in situ hybridization (FISH) analysis, a high percentage of tumoral 
      BM PC from untreated patients was found to express CD106. In addition, these 
      cells also expressed an activated form of CD29, as determined using the CD29 
      activation reporter monoclonal antibody HUTS-21. Adhesion-binding experiments 
      showed that CD106+-activated CD29+ BM PC from these patients adhered to 
      fibronectin (FN) in a CD29/CD49d-dependent manner. In contrast, marrow PC from 
      progressive patients and BM or circulating malignant cells from secondary PCL 
      patients expressed lower levels or were negative for CD106 and activated CD29, 
      respectively, with a decreased or zero ability to adhere to FN. The expression of 
      constitutive CD29 and CD49d, however, was similar during disease progression. We 
      conclude that BM myelomatous cells co-express CD106 and a functionally active 
      form of CD29. Moreover, our results suggest that the loss of expression and/or 
      function of these antigens are associated with the progression of MM and may 
      explain the exit of tumoral cells from the BM.
FAU - Luque, Rosario
AU  - Luque R
AD  - Servicio de Inmunologia, Hospital Ramon y Cajal, Madrid, Spain.
FAU - Garcia-Trujillo, Jose Antonio
AU  - Garcia-Trujillo JA
FAU - Camara, Carmen
AU  - Camara C
FAU - Moreno, Ana
AU  - Moreno A
FAU - Eiras, Pablo
AU  - Eiras P
FAU - Roy, Garbine
AU  - Roy G
FAU - Villar, Luisa Maria
AU  - Villar LM
FAU - Lombardia, Manuel
AU  - Lombardia M
FAU - Brieva, Jose Antonio
AU  - Brieva JA
FAU - Bootello, Alfredo
AU  - Bootello A
FAU - Roldan, Ernesto
AU  - Roldan E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Fibronectins)
RN  - 0 (Integrin beta1)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
SB  - IM
MH  - Bone Marrow Cells/*metabolism
MH  - Cell Adhesion
MH  - Disease Progression
MH  - Down-Regulation
MH  - Fibronectins/metabolism
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Integrin beta1/*metabolism
MH  - Multiple Myeloma/*metabolism/pathology
MH  - Plasma Cells/metabolism
MH  - Recurrence
MH  - Vascular Cell Adhesion Molecule-1/*metabolism
EDAT- 2002/10/03 04:00
MHDA- 2002/12/17 04:00
CRDT- 2002/10/03 04:00
PHST- 2002/10/03 04:00 [pubmed]
PHST- 2002/12/17 04:00 [medline]
PHST- 2002/10/03 04:00 [entrez]
AID - 3792 [pii]
AID - 10.1046/j.1365-2141.2002.03792.x [doi]
PST - ppublish
SO  - Br J Haematol. 2002 Oct;119(1):70-8. doi: 10.1046/j.1365-2141.2002.03792.x.